Anaplastic Thyroid Carcinoma, Version 2.2015

J Natl Compr Canc Netw. 2015 Sep;13(9):1140-50. doi: 10.6004/jnccn.2015.0139.

Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.

Publication types

  • Practice Guideline

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / administration & dosage
  • Docetaxel
  • Doxorubicin / administration & dosage
  • Humans
  • Paclitaxel / administration & dosage
  • Radiotherapy, Intensity-Modulated
  • Taxoids / administration & dosage
  • Thyroid Carcinoma, Anaplastic / diagnosis*
  • Thyroid Carcinoma, Anaplastic / secondary
  • Thyroid Carcinoma, Anaplastic / therapy*
  • Thyroid Neoplasms / diagnosis*
  • Thyroid Neoplasms / pathology
  • Thyroid Neoplasms / therapy*
  • Thyroidectomy

Substances

  • Taxoids
  • Docetaxel
  • Doxorubicin
  • Carboplatin
  • Paclitaxel